




INNOVATION
Distinguishes between
LEADER and follower



For Healthcare Professionals only

ZURCAL[®]


Pantoprazole

Confidence from the start



 **AUG**
PHARMA

 **ZURCAL[®]**
Pantoprazole



What's **Victory** Without **Both**

AUGISPOV
Sofosbuvir 400 mg


OLYSIO
SIMEPREVIR

Now The Optimum Cure For HEP C In One Set

G-Sac

Silymarin 140mg + Multivitamins

*from
Care
to Repair*



 **AUG**
PHARMA

AUGIDACLA
Daclatasvir 60mg

AUGIDACLA

Daclatasvir 60mg



28 film coated tablets

Introducing **Qurevo**[®]:

A New Face of Cure in Chronic HCV



INDICATIONS:¹

Qurevo[®] is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults

Qurevo[®]

ombitasvir 12.5 mg/
paritaprevir 75 mg/ritonavir 50 mg film-coated tablets.

abbvie



MPIVIROPACK PLUS

Sofosbuvir 400mg
Ledipasvir 90 mg



The Master Scene in HCV Mass Eradication.

The FIRST Single Pill Combination
DAAS for HCV Mass Eradication in Egypt



Same cost effectiveness
Better Patients' Convenience



Now available

New Pack

14 Tabs "2 Strips"

Price 40 EGP/7 Tabs



Pariet®
20 mg

Fast onset of action
with sustained acid suppression.^{1,2}

Is indicated for the treatment of: Active duodenal ulcer; active benign gastric ulcer; symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD); Gastro-Oesophageal Reflux Disease Long-term Management (GORD Maintenance); symptomatic gastro-oesophageal reflux disease (symptomatic GORD); in combination with appropriate antibacterial therapeutic regimens for the eradication of *Helicobacter pylori* in patients with peptic ulcer disease or chronic gastritis; the healing and the prevention of relapse of peptic ulcers in patients with *H. pylori* associated ulcers.³

1. Pace F, Palotta S, Casali S, Porro GB. A review of rabeprazole in the treatment of acid related diseases. *Therapeutics and Clinical Risk Management* 2007; 3 (3): 363-379.

2. Meier P, Delmon B, Xiao J, Lococo J, Ima J. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of acid reflux. *Alimentary Pharmacology and Therapeutics* 2010; 31: 991-1000.

3. Pariet® local prescribing information.



janssen

Full prescribing information within the RDA is available
Please refer to the Janssen website for the full
41- Mohamed Tawfik, dab et. New City - Cairo
Email: janss@janss-jp.com



Pariet®
rabeprazole 20 mg

WORKS AT THE MOMENT



Pariet® (rabeprazole) has an early onset of acid inhibition, within 5 minutes with more than 80% of the proton pumps are inhibited.¹

Is indicated for the treatment of: Active duodenal ulcer; active benign gastric ulcer; symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD); Long-term Management (GORD Maintenance); symptomatic gastro-oesophageal reflux disease (symptomatic GORD). In combination with appropriate antibacterial regimens for the eradication of *Helicobacter pylori* in patients with peptic ulcer disease or chronic gastritis; the healing and the prevention of relapse of peptic ulcers in patients with *H. pylori* associated ulcers.²

In acid related disorders

WORKS EVERY MOMENT



In GERD patients with nocturnal heartburn a single dose of Pariet® (rabeprazole) 20 mg was significantly more effective than pantoprazole 40 mg during the 24 hour postdose period.¹

¹ Almer P, Odensten B, Wang J, Lonnroth J, Wei J. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. *Aliment Pharmacol Ther* 2010; 31: 991-1000.

² Pariet® local prescribing information.

Janssen

Full prescribing information within the RDA is available upon request from Janssen scientific office.
For adverse events, please contact local safety unit.
41- Mohamed Swaidi, dr. H. El-Nasr City - Cairo
E-mail: jscg-pr@its.jnj.com

MotiliumTM
DOMPERIDONE
LifeTime of Care

Is indicated for the relief of the symptoms of nausea and vomiting.¹



1. MotiliumTM DomperidoneTM prescription information, Janssen Pharmaceutical Egypt, March 2015.



Full prescribing information within the RDA is available upon request from Janssen scientific office.
For adverse events, please contact local safety unit.
41- Mohamed tawfik diab st. Nasr City - Cairo
Landline: +202 2270 7670
E-mail: jaceg-pv@its.jnj.com

DRIVING MOTILITY



NOW AVAILABLE


Resolor™
prucalopride

Motility matters in chronic constipation
Resolor™ is indicated for symptomatic
treatment of chronic constipation
in adults whom laxatives fail to
provide adequate relief¹



**RESOLOR™ (PRUCALOPRIDE) IS A HIGHLY SELECTIVE SEROTONIN 5-HT₄ RECEPTOR
AGONIST WHICH HAS BEEN SHOWN TO STIMULATE GUT MOTILITY²**

1. Resolor™ 'Prucalopride' prescription information, Janssen Pharmaceutical Egypt, June 2015.
2. Quigley EM. Prucalopride: safety, efficacy and potential applications. *Therap Adv Gastroenterol* 2012; 5 (1): 23-30.

Janssen


Full prescribing information within the RDA is available
upon request from Janssen scientific office.
For adverse events, please contact local safety unit:
41- Mohamed Faruk Elsh St. Nasa City - Cairo
Landline: +202 2270 7670
E-mail: jpxeg-pv@its.jnj.com

14th EDDW

OFFICIAL ORGANIZER

OFFICIAL ORGANIZER



ALFA MEDICAL

53 El-Makrizy Street, Roxy, Doctors Tower, 4th Floor, Flat 414, Cairo, Egypt

CAIRO OFFICE

Land Lines : Tel. : +20 (2) 24 532 916 / 917 - Fax : +20 (2) 24 533 515

Project Manager : Mob : +20 (10) 222 40 575 - Email : alfa@alfamedical.org

Information : Mob : +20 (10) 222 40 576 - Email : info@alfamedical.org

+20 (10) 222 40 574 - accounts@alfamedical.org

WWW.ALFAMEDICAL.ORG

14th EDDW



**The Egyptian Society for the Study
of Endoscopy and Hepatogastroenterology**